MediWound Expands Manufacturing Capacity for NexoBrid
MediWound Ltd., a pioneering company in the field of enzymatic therapeutics, has successfully completed the important commissioning process for its extended GMP manufacturing facility. This advancement marks a significant moment for the organization, setting the stage for achieving a remarkable sixfold increase in production capacity aimed to tackle the rising global demand for NexoBrid.
A Step Toward Operational Readiness
Located in a strategic region, this newly expanded facility is an essential step towards full operational readiness anticipated by the end of the upcoming year. Shmulik Hess, Ph.D., the Chief Operating and Commercial Officer of MediWound, expressed enthusiasm about this milestone. He stated that the successful completion of the facility not only supports operational excellence but also confirms the company's dedication to providing timely access to NexoBrid for healthcare professionals and patients around the world.
Meeting Global Demand for NexoBrid
The enhanced facility is designed to significantly increase the production of NexoBrid, a cutting-edge treatment used in managing thermal burns. This expansion will allow MediWound to maintain a reliable and scalable global supply of the product, which is currently approved in over 40 markets worldwide. The company is looking forward to addressing the anticipated demand for this vital therapeutic solution, ensuring that patients receive the care they require.
Understanding NexoBrid’s Significance
NexoBrid is not just another product in the market; it is a topically applied enzyme-based treatment aimed at the effective removal of eschar in patients suffering from deep partial and full-thickness thermal burns. Its unique formulation selectively removes non-viable tissue while actively preserving healthy tissue, translating to better recovery outcomes for patients. This product, a biological orphan drug, has garnered approval for use in both adult and pediatric patients across major global regions including the United States, the European Union, and Japan.
MediWound's Commitment to Innovation
As a dynamic player in biotechnology, MediWound is committed to developing and commercializing enzyme therapies that offer improved treatment options for non-surgical tissue repair. Apart from NexoBrid, the company is also progressing with EscharEx, which is an investigational therapy aimed at treating chronic wounds. It has been noted that EscharEx showcases various clinical advantages when compared to other existing enzymatic debridement products, thus opening the door for expansive market opportunities.
Contact Information for MediWound
For more insights into MediWound’s products and developments, the company's contact channels are open for inquiries:
MediWound Contacts:
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008
Frequently Asked Questions
What is the purpose of the expanded facility at MediWound?
The expanded facility aims to significantly increase the production capacity for NexoBrid to meet growing global demands.
What is NexoBrid?
NexoBrid is a topically applied biological orphan drug used for the enzymatic removal of eschar in patients suffering from thermal burns.
What markets approve the use of NexoBrid?
NexoBrid is approved in over 40 markets, including regions like the United States, European Union, and Japan.
What other products is MediWound developing?
MediWound is also developing EscharEx, an investigational therapy for chronic wound debridement, which demonstrates clinical advantages over current treatments.
When is the facility expected to be fully operational?
The expanded facility is projected to achieve full operational readiness by the end of next year.
